A Phase 2, Randomized, Open-Label Study of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Subjects With Chronic Genotype 1 HCV Infection and Cirrhosis
Phase of Trial: Phase II
Latest Information Update: 08 Mar 2016
Price : $35 *
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary) ; Vedroprevir (Primary) ; Ribavirin
- Indications Hepatitis C; Liver cirrhosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Gilead Sciences
- 22 Feb 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 07 Oct 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 29 Aug 2014 New trial record